⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGIO News
Agios Pharmaceuticals, Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
accessnewswire.com
AGIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
globenewswire.com
AGIO
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Agios Pharmaceuticals, Inc. (AGIO) And Encourages Stockholders to Reach Out
accessnewswire.com
AGIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
accessnewswire.com
AGIO
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
globenewswire.com
AGIO
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
globenewswire.com
BHVN
AGIO
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
globenewswire.com
AGIO
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
globenewswire.com
AGIO
Form 8-K
sec.gov
AGIO
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
globenewswire.com
AGIO